STAT3 phosphorylation in central leptin resistance

H Liu, T Du, C Li, G Yang - Nutrition & metabolism, 2021 - Springer
Mechanism exploitation of energy homeostasis is urgently required because of the
worldwide prevailing of obesity-related metabolic disorders in human being. Although it is …

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Y Hu, Z Dong, K Liu - Journal of Experimental & Clinical Cancer Research, 2024 - Springer
Signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor involved
in almost all cancer hallmark features including tumor proliferation, metastasis …

Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers

M Brachet-Botineau, M Polomski, HA Neubauer… - Cancers, 2020 - mdpi.com
Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors of
cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated …

STAT3 activation and oncogenesis in lymphoma

F Zhu, KB Wang, L Rui - Cancers, 2019 - mdpi.com
Signal transducer and activator of transcription 3 (STAT3) is an important and the most
studied transcription factor in the Janus kinase (JAK)/STAT signaling pathway. STAT3 …

Transcription factors in cancer: when alternative splicing determines opposite cell fates

S Belluti, G Rigillo, C Imbriano - Cells, 2020 - mdpi.com
Alternative splicing (AS) is a finely regulated mechanism for transcriptome and proteome
diversification in eukaryotic cells. Correct balance between AS isoforms takes part in …

[HTML][HTML] PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia

C Carlock, Y Bai, A Paige-Hood, Q Li, FN Meke… - JCI insight, 2023 - ncbi.nlm.nih.gov
Overexpression of phosphatases of regenerating liver 2 (PRL2), detected in numerous
diverse cancers, is often associated with increased severity and poor patient prognosis …

STAT3, the challenge for chemotherapeutic and radiotherapeutic efficacy

PL Yang, LX Liu, EM Li, LY Xu - Cancers, 2020 - mdpi.com
Simple Summary STAT3, an oncogene, contributes to insensitivity of chemotherapy and
radiotherapy in tumor, reduces the clinical efficacy. Meanwhile, STAT3β, a STAT3 splicing …

The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis

CJ Stavast, I van Zuijen, E Karkoulia, A Özçelik… - Leukemia, 2022 - nature.com
MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML).
However, the tumor-suppressing activities of miR-139 and molecular mechanisms of …

STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance

A Witalisz-Siepracka, CM Denk, B Zdársky… - Frontiers in …, 2024 - frontiersin.org
Acute myeloid leukemia (AML) is a heterogenous disease characterized by the clonal
expansion of myeloid progenitor cells. Despite recent advancements in the treatment of …

The ups and downs of STAT inhibition in acute myeloid leukemia

B Moser, S Edtmayer, A Witalisz-Siepracka, D Stoiber - Biomedicines, 2021 - mdpi.com
Aberrant Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling
is implicated in the pathogenesis of acute myeloid leukemia (AML), a highly heterogeneous …